Wegovy-maker Novo Nordisk buys land in Denmark for potential new production plant
COPENHAGEN, July 23 (Reuters) -Novo Nordisk NOVOb.CO, the maker of weight-loss drug Wegovy, has bought a site in Denmark's third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tuesday,
Novo last year became Europe's most valuable company due to the success of its weight-loss treatment Wegovy and diabetes drug Ozempic.
The company has spent billions to boost production - mostly in its native Denmark and in the United States - as it has struggled to meet huge demand.
Odense will be a new site for the drug maker.
"With the political processes and approvals in place, we are pleased to announce that Novo Nordisk is now the owner of the site in Tietgenbyen in Odense," the company said in an emailed statement.
Novo expects to make a final investment decision at the end of the year, it said.
Reporting by Jacob Gronholt-Pedersen; Editing by Kirsten Donovan
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
